Novocure has signed a long-term supply agreement with ITT Electronic Systems for its NovoTTF-100A System.

Under the agreement, ITT Electronic Systems will supply piezoelectric ceramic components to manufacture the disposable electrodes for Novocure’s NovoTTF-100A System.

NovoTTF-100A System, an FDA approved device, is used to treat adult patients with recurrent glioblastoma brain tumors (GBM).

The system comprises of an electronic field generator, disposable electrodes and related accessories.

The NovoTTF-100A electrodes integrate sensors to deliver electric fields to target tissues within parameters known to be safe and therapeutically effective and are insulated to prevent transmission of electric currents.

Novocure COO Mike Ambrogi said ITT Electronic Systems was able to adapt piezoelectric ceramic electrode sensing technology from a military application to meet their technical specifications.